Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Advanced Pretreated Malignant Pleural Mesothelioma
NCT04115111Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in malignant pleural mesothelioma (MPM), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Proportion of survived patients at 16 weeks. Started Oct 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04115111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115111.